Supira Medical Inc is a private cardiovascular device company developing an investigational percutaneous ventricular assist device, or pVAD, for high-risk percutaneous coronary intervention and cardiogenic shock. This weekly summary reviews the company’s latest clinical, technical, and conference-related updates.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
During the week, Supira reported that its SUPPORT II Pivotal Study for high-risk PCI has begun enrolling patients at multiple U.S. centers, including Montefiore Health System, Oklahoma Heart Institute, and UC Davis Health. This marks a key step in advancing clinical validation of the Supira System and could underpin future regulatory submissions if outcomes are favorable.
The company also highlighted peer-reviewed clinical evidence in Circulation: Cardiovascular Interventions documenting successful use of its investigational device in complex cardiac cases. Publication in a major cardiology journal supports the platform’s emerging credibility and may help build confidence among interventional cardiologists and heart failure specialists.
Across its communications, Supira emphasized design features intended to balance strong hemodynamic support with less invasive access, including a custom low-profile 10Fr introducer, up to 5.5 liters per minute of continuous flow, and dual sensors for real-time aortic and ventricular pressure monitoring. These elements are positioned as potential differentiators within the mechanical circulatory support segment.
The company used the PCR cardiology meeting and Innovator’s Day to engage with physicians, collaborators, and industry leaders on the future of cardiovascular care and the role of its pVAD platform. CEO Nitin Salunke’s participation in an Innovator’s Exchange Hub panel and broader networking efforts may help refine product-market fit and foster strategic relationships, though no specific commercial deals were disclosed.
Supira reiterated that the Supira System remains an investigational device and is not approved for sale in the U.S. or any other market, so current milestones are focused on data generation rather than revenue. Overall, the week represented a constructive period of clinical progress, growing evidence, and increased industry visibility for Supira Medical as it moves toward potential future commercialization.